The company’s co-founders said they are leaving to start a new mRNA-based company.

By Ludwig Burger and Patricia Weiss FRANKFURT, March 10 (Reuters) - BioNTech's two co-founders and leading executives will ...

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

The founders of German vaccine manufacturer BioNTech, which became famous worldwide for its coronavirus jab, are to step down to start a new business, the company said on Tuesday. Ugur Sahin and Özlem ...

March 11 (Reuters) - A key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA ‌vaccines, the Washington Post reported on Wednesday, citing two people familiar with the matter.

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...